JP2016515562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515562A5 JP2016515562A5 JP2016504671A JP2016504671A JP2016515562A5 JP 2016515562 A5 JP2016515562 A5 JP 2016515562A5 JP 2016504671 A JP2016504671 A JP 2016504671A JP 2016504671 A JP2016504671 A JP 2016504671A JP 2016515562 A5 JP2016515562 A5 JP 2016515562A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- substituted
- methyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methoxy, difluoromethoxy Chemical group 0.000 claims 64
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 18
- 229910052731 fluorine Inorganic materials 0.000 claims 16
- 239000011737 fluorine Substances 0.000 claims 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 15
- 229910052801 chlorine Inorganic materials 0.000 claims 15
- 239000000460 chlorine Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 3
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000006069 Suzuki reaction reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161588.2 | 2013-03-28 | ||
| EP13161588 | 2013-03-28 | ||
| EP13190944 | 2013-10-30 | ||
| EP13190944.2 | 2013-10-30 | ||
| PCT/EP2014/056135 WO2014154794A1 (de) | 2013-03-28 | 2014-03-27 | Substituierte oxopyridin-derivate und ihre verwendung bei der behandlung von herz-kreislauf-erkrankungen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017242345A Division JP6633045B2 (ja) | 2013-03-28 | 2017-12-19 | 置換されたオキソピリジン誘導体およびそれの心血管障害の治療における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515562A JP2016515562A (ja) | 2016-05-30 |
| JP2016515562A5 true JP2016515562A5 (enExample) | 2017-03-30 |
| JP6266086B2 JP6266086B2 (ja) | 2018-01-24 |
Family
ID=50390087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504671A Expired - Fee Related JP6266086B2 (ja) | 2013-03-28 | 2014-03-27 | 置換されたオキソピリジン誘導体およびそれの心血管障害の治療における使用 |
| JP2017242345A Expired - Fee Related JP6633045B2 (ja) | 2013-03-28 | 2017-12-19 | 置換されたオキソピリジン誘導体およびそれの心血管障害の治療における使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017242345A Expired - Fee Related JP6633045B2 (ja) | 2013-03-28 | 2017-12-19 | 置換されたオキソピリジン誘導体およびそれの心血管障害の治療における使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9434690B2 (enExample) |
| EP (1) | EP2978756B1 (enExample) |
| JP (2) | JP6266086B2 (enExample) |
| KR (1) | KR20150137095A (enExample) |
| CN (2) | CN108164513B (enExample) |
| AP (1) | AP2015008782A0 (enExample) |
| AU (1) | AU2014242971B2 (enExample) |
| BR (1) | BR112015024414A2 (enExample) |
| CA (1) | CA2908085C (enExample) |
| CL (1) | CL2015002855A1 (enExample) |
| CR (1) | CR20150476A (enExample) |
| DO (1) | DOP2015000246A (enExample) |
| EA (1) | EA028034B9 (enExample) |
| ES (1) | ES2731819T3 (enExample) |
| MX (1) | MX2015013437A (enExample) |
| NI (1) | NI201500143A (enExample) |
| PE (1) | PE20151758A1 (enExample) |
| PH (1) | PH12015502249A1 (enExample) |
| SG (2) | SG11201506879RA (enExample) |
| TN (1) | TN2015000434A1 (enExample) |
| TW (1) | TWI633089B (enExample) |
| UA (1) | UA115902C2 (enExample) |
| UY (1) | UY35508A (enExample) |
| WO (1) | WO2014154794A1 (enExample) |
| ZA (1) | ZA201507155B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| WO2015120777A1 (zh) * | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| WO2016046158A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2016046156A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CA2979937A1 (en) * | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (de) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| FR3046791B1 (fr) * | 2016-01-18 | 2020-01-10 | Adisseo France S.A.S. | Procede de preparation d'analogues de la methionine |
| CN113912586B (zh) * | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| US11299462B2 (en) | 2018-02-27 | 2022-04-12 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of oxopicolinamide derivative and preparation method therefor |
| CN110193012B (zh) * | 2018-02-27 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法 |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| KR102807521B1 (ko) | 2018-03-15 | 2025-05-16 | 바이엘 악티엔게젤샤프트 | 2종의 4-｛[(2s)-2-｛4-[5-클로로-2-(1h-1,2,3-트리아졸-1-일)페닐]-5-메톡시-2-옥소피리딘-1(2h)-일}부타노일]아미노}-2-플루오로벤즈아미드 유도체의 제조 방법 |
| DK3774796T3 (da) | 2018-04-10 | 2022-07-18 | Bayer Pharma AG | Et substitueret oxopyridinderivat |
| EA202191764A1 (ru) | 2018-12-21 | 2021-10-22 | Байер Акциенгезельшафт | Замещенные оксопиридиновые производные |
| WO2020127508A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
| CN112047931B (zh) * | 2019-06-06 | 2024-03-08 | 上海美悦生物科技发展有限公司 | FXIa凝血因子抑制剂、其药物组合物和用途 |
| CN112341377B (zh) * | 2019-08-09 | 2024-05-14 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物及其应用 |
| GB201911816D0 (en) * | 2019-08-16 | 2019-10-02 | Univ London Queen Mary | Treatment |
| EP4036087A4 (en) * | 2019-09-27 | 2023-09-20 | Shenzhen Salubris Pharmaceuticals Co. Ltd | FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF |
| CN112940431B (zh) * | 2021-02-04 | 2023-03-10 | 四川大学 | 一种激光诱导的荧光发射组合物及图案化荧光发射方法 |
| CN115108977B (zh) * | 2021-03-19 | 2024-11-29 | 南京正大天晴制药有限公司 | 一种瑞戈非尼的制备方法 |
| CN114920699B (zh) * | 2022-05-31 | 2024-03-19 | 甘肃皓天科技股份有限公司 | 一种制备6-氯-2-甲基-2h-吲唑-5-胺的方法 |
| CN116262740A (zh) * | 2022-11-18 | 2023-06-16 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| JP2026524091A (ja) | 2023-06-09 | 2026-07-17 | チォンドウ シーベイカン バイオメディカル テクノロジー カンパニー リミテッド | オキソピリジン系化合物の新規製造方法及びキー中間体と応用 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
| WO2026119653A1 (en) | 2024-12-02 | 2026-06-11 | Bayer Aktiengesellschaft | Preparative process |
| WO2026119652A1 (en) | 2024-12-02 | 2026-06-11 | Bayer Aktiengesellschaft | Preparative process |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010113970A (ko) * | 1999-05-19 | 2001-12-28 | 추후보정 | 응고 캐스케이드의 선택적 억제에 유용한 치환 폴리시클릭아릴 및 헤테로아릴 피리돈 |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7361672B2 (en) * | 2004-12-23 | 2008-04-22 | Hoffmann-La Roche Inc. | Heteroarylacetamide inhibitors of factor Xa |
| EP2016072B1 (en) * | 2006-05-05 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| WO2011077711A1 (ja) * | 2009-12-22 | 2011-06-30 | 興和株式会社 | 新規な２－ピリドン誘導体及びこれを含有する医薬 |
| WO2013093484A1 (en) * | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
| CA2880898A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| US9809545B2 (en) * | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
-
2014
- 2014-03-26 TW TW103111168A patent/TWI633089B/zh not_active IP Right Cessation
- 2014-03-27 UY UY0001035508A patent/UY35508A/es not_active Application Discontinuation
- 2014-03-27 EP EP14713452.2A patent/EP2978756B1/de active Active
- 2014-03-27 ES ES14713452T patent/ES2731819T3/es active Active
- 2014-03-27 SG SG11201506879RA patent/SG11201506879RA/en unknown
- 2014-03-27 AP AP2015008782A patent/AP2015008782A0/xx unknown
- 2014-03-27 CN CN201711458259.0A patent/CN108164513B/zh not_active Expired - Fee Related
- 2014-03-27 AU AU2014242971A patent/AU2014242971B2/en not_active Ceased
- 2014-03-27 WO PCT/EP2014/056135 patent/WO2014154794A1/de not_active Ceased
- 2014-03-27 JP JP2016504671A patent/JP6266086B2/ja not_active Expired - Fee Related
- 2014-03-27 CA CA2908085A patent/CA2908085C/en active Active
- 2014-03-27 BR BR112015024414A patent/BR112015024414A2/pt not_active Application Discontinuation
- 2014-03-27 MX MX2015013437A patent/MX2015013437A/es unknown
- 2014-03-27 PE PE2015002065A patent/PE20151758A1/es not_active Application Discontinuation
- 2014-03-27 CN CN201480025730.5A patent/CN105164122B/zh not_active Expired - Fee Related
- 2014-03-27 US US14/780,925 patent/US9434690B2/en not_active Expired - Fee Related
- 2014-03-27 KR KR1020157030938A patent/KR20150137095A/ko not_active Withdrawn
- 2014-03-27 SG SG10201710895UA patent/SG10201710895UA/en unknown
- 2014-03-27 UA UAA201510454A patent/UA115902C2/uk unknown
- 2014-03-27 EA EA201591874A patent/EA028034B9/ru not_active IP Right Cessation
-
2015
- 2015-09-11 CR CR20150476A patent/CR20150476A/es unknown
- 2015-09-18 DO DO2015000246A patent/DOP2015000246A/es unknown
- 2015-09-18 NI NI201500143A patent/NI201500143A/es unknown
- 2015-09-22 TN TN2015000434A patent/TN2015000434A1/en unknown
- 2015-09-24 PH PH12015502249A patent/PH12015502249A1/en unknown
- 2015-09-24 CL CL2015002855A patent/CL2015002855A1/es unknown
- 2015-09-28 ZA ZA2015/07155A patent/ZA201507155B/en unknown
-
2016
- 2016-09-04 US US15/256,608 patent/US9822102B2/en not_active Expired - Fee Related
-
2017
- 2017-10-17 US US15/786,352 patent/US10183932B2/en active Active
- 2017-12-19 JP JP2017242345A patent/JP6633045B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519323A5 (enExample) | ||
| JP2016535031A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2017528496A5 (enExample) | ||
| CA2724192A1 (en) | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors | |
| DK3009426T3 (en) | 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICINE COMPREHENSIVE AS AN ACTIVE INGREDIENT | |
| JP2016535732A5 (enExample) | ||
| CA2680697A1 (en) | Substituted imidazopyrimidines and triazolopyrimidines | |
| JP2009515988A5 (enExample) | ||
| NZ628077A (en) | Treatment of immune-related and inflammatory diseases | |
| JP2014506599A5 (enExample) | ||
| RU2013123275A (ru) | Пиперидин-4-илазетидиндиамиды как ингибиторы моноацилглицеринлипазы | |
| JP2016540742A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| RU2018114289A (ru) | Бициклические соединения в качестве ингибиторов аутотаксина (atx) | |
| JP2016503785A5 (enExample) | ||
| JP2011506566A5 (enExample) | ||
| CA2554049A1 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| JP2012507535A5 (enExample) | ||
| RU2018106948A (ru) | Способ получения замещенных производных 3-(2-анилино-1-циклогексил -1н-бензимидазол-5-ил)пропановой кислоты | |
| TW202340150A (zh) | 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之吲哚、吲唑及相關類似物 | |
| JP2017519818A5 (enExample) | ||
| EP2576536A2 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
| JP2016518317A5 (enExample) |